Reuters logo
AstraZeneca to buy 55 pct of cancer firm Acerta for $4.0 bln
December 17, 2015 / 7:44 AM / 2 years ago

AstraZeneca to buy 55 pct of cancer firm Acerta for $4.0 bln

LONDON, Dec 17 (Reuters) - AstraZeneca said on Thursday it had agreed to buy a 55 percent stake in privately held biotech firm Acerta Pharma for $4.0 billion to give it access to a new kind of drug for fighting blood cancers.

AstraZeneca will pay $2.5 billion upfront, with a further $1.5 billion paid either on receipt of the first regulatory approval for the medicine acalabrutinib or at the end of 2018, depending on which is first. (Reporting by Ben Hirschler; editing by Jason Neely)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below